momo-T/FIF Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (3070)	9/14/2005 4:00:22 PM
From: former_pgs	Read Replies (1) of 12215

The blood-related side effects were a large concern to me when the mds data first came out. Why treat people for MDS with a drug that is going to (almost assuredly) give them grade 3/4 thrombocytopenia? Regardless, the answer to Question #2 makes me think along boronate's train of thought. If the FDA can't write a label with a recommended dose, how can they rule for full approval of the drug? Another trial on the way? For the brave, this is a great CELG short opportunity. I'm not sure the market realizes the impact of Question #2 yet.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next